
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1945595/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emerging epidemic of type 2 diabetes in youth. Diabetes Care, 1999, 22, 345-354.	4.3	913
2	Growth Hormone (GH) Insensitivity Due to Primary GH Receptor Deficiency. Endocrine Reviews, 1994, 15, 369-390.	8.9	456
3	Limited Joint Mobility in Childhood Diabetes Mellitus Indicates Increased Risk for Microvascular Disease. New England Journal of Medicine, 1981, 305, 191-194.	13.9	410
4	Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatric Diabetes, 2014, 15, 154-179.	1.2	295
5	Diabetic ketoacidosis in children and adolescents with diabetes. Pediatric Diabetes, 2009, 10, 118-133.	1.2	265
6	Cerebral Edema in Childhood Diabetic Ketoacidosis: Natural history, radiographic findings, and early identification. Diabetes Care, 2004, 27, 1541-1546.	4.3	183
7	Joint contracture—common manifestation of childhood diabetes mellitus. Journal of Pediatrics, 1976, 88, 584-588.	0.9	173
8	Diabetic ketoacidosis. Pediatric Diabetes, 2007, 8, 28-43.	1.2	156
9	The Little Women of Loja — Growth Hormone–Receptor Deficiency in an Inbred Population of Southern Ecuador. New England Journal of Medicine, 1990, 323, 1367-1374.	13.9	150
10	Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. Human Mutation, 1992, 1, 24-34.	1.1	132
11	Type 2 diabetes mellitus in the child and adolescent. Pediatric Diabetes, 2008, 9, 512-526.	1.2	122
12	Hyperglycemic Hyperosmolar Syndrome in Children: Pathophysiological Considerations and Suggested Guidelines for Treatment. Journal of Pediatrics, 2011, 158, 9-14.e2.	0.9	110
13	Two-Year Treatment of Growth Hormone (GH) Receptor Deficiency with Recombinant Insulin-Like Growth Factor I in 22 Children: Comparison of Two Dosage Levels and to GH-Treated GH Deficiency ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 629-633.	1.8	106
14	Childhood Obesity. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4211-4218.	1.8	105
15	Hyperglycemic Hyperosmolar State: An Emerging Pediatric Problem. Journal of Pediatrics, 2010, 156, 180-184.	0.9	105
16	Bone Mineral, Histomorphometry, and Body Composition in Adults with Growth Hormone Receptor Deficiency. Journal of Bone and Mineral Research, 1998, 13, 415-421.	3.1	102
17	Clinical and Biochemical Phenotype of Familial Anterior Hypopituitarism from Mutation of the PROP1 Gene ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 50-57.	1.8	95
18	Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. Journal of Pediatrics, 2004, 144, 270-273.	0.9	82

#	Article	IF	CITATIONS
19	Cerebral adema complicating diabetic ketoacidosis in childhood. Journal of Pediatrics, 1980, 96, 357-361.	0.9	78
20	The management of diabetic ketoacidosis in children. Diabetes Therapy, 2010, 1, 103-120.	1.2	75
21	Hyperglycemic Crises and their Complications in Children. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 5-18.	0.4	67
22	Diabetic Ketoacidosis (DKA): Treatment Guidelines. Clinical Pediatrics, 1996, 35, 261-266.	0.4	65
23	Limited joint mobility in diabetes mellitus of childhood: Natural history and relationship to growth impairment. Journal of Pediatrics, 1982, 101, 874-878.	0.9	61
24	Type 2 diabetes mellitus among Florida children and adolescents, 1994 through 1998. Public Health Reports, 2002, 117, 373-379.	1.3	59
25	Mecasermin (recombinant human insulin-like growth factor I). Advances in Therapy, 2009, 26, 40-54.	1.3	58
26	Increasing Incidence of Type 2 Diabetes in Children and Adolescents. Paediatric Drugs, 2002, 4, 209-221.	1.3	55
27	Normal Intelligence with Severe Insulin-Like Growth Factor I Deficiency due to Growth Hormone Receptor Deficiency: A Controlled Study in a Genetically Homogeneous Population1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1953-1958.	1.8	54
28	GH Receptor Deficiency in Ecuadorian Adults Is Associated With Obesity and Enhanced Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2589-2596.	1.8	54
29	Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. Journal of Pediatrics, 2001, 138, 33-37.	0.9	53
30	Treatment of Type 2 Diabetes Mellitus in Children and Adolescents. Journal of Pediatric Endocrinology and Metabolism, 2000, 13, 1403-1410.	0.4	52
31	Growth Hormone Receptor Deficiency in Ecuador1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4436-4443.	1.8	51
32	Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. Journal of Pediatrics, 1998, 132, 944-947.	0.9	50
33	Congenital pancreatic hypoplasia: A syndrome of exocrine and endocrine pancreatic insufficiency. Journal of Pediatrics, 1986, 109, 465-468.	0.9	44
34	Type 2 diabetes in children. Current Diabetes Reports, 2001, 1, 19-27.	1.7	43
35	Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency. Diabetologia, 2015, 58, 37-42.	2.9	43
36	Growth in growth hormone insensitivity. Trends in Endocrinology and Metabolism, 1994, 5, 296-303.	3.1	41

#	Article	IF	CITATIONS
37	GROWTH HORMONE INSENSITIVITY. Pediatric Clinics of North America, 1997, 44, 423-442.	0.9	41
38	Lessons from the Genetics of Laron Syndrome. Trends in Endocrinology and Metabolism, 1998, 9, 276-283.	3.1	34
39	Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature?. Lancet, The, 2006, 368, 612-616.	6.3	34
40	The role of recombinant insulin-like growth factor I in the treatment of the short child. Current Opinion in Pediatrics, 2007, 19, 458-464.	1.0	32
41	Growth hormone insensitivity: Physiologic and genetic basis, phenotype, and treatment. Journal of Pediatrics, 1999, 135, 280-289.	0.9	30
42	Recombinant Human Insulin-Like Growth Factor I (rhIGF-I) and rhIGF-I/rhIGF-Binding-Protein-3: New Growth Treatment Options?. Journal of Pediatrics, 2007, 150, 7-11.	0.9	28
43	Type 2 diabetes mellitus among Florida children and adolescents, 1994 through 1998. Public Health Reports, 2002, 117, 373-9.	1.3	28
44	Longâ€ŧerm effects of insulinâ€ŀike growth factor (IGF)â€ŀ treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency. Clinical Endocrinology, 1995, 42, 399-407.	1.2	27
45	Fatal cerebral infarctions in diabetic ketoacidosis in a child with previously unknown heterozygosity for factor V Leiden deficiency. Journal of Pediatrics, 2004, 145, 561-562.	0.9	27
46	Limited Joint Mobility in Childhood Diabetes: Discovery, Description, and Decline. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 466-473.	1.8	27
47	correlates of biopsy-studied nephropathy in young patients with insulin-dependent diabetes mellitus. Journal of Pediatrics, 1985, 106, 196-201.	0.9	25
48	Stature in Ecuadorians Heterozygous for Growth Hormone Receptor Gene E180 Splice Mutation Does Not Differ From That of Homozygous Normal Relatives1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2373-2375.	1.8	25
49	Idiopathic Short Stature: Conundrums of Definition and Treatment. International Journal of Pediatric Endocrinology (Springer), 2009, 2009, 1-5.	1.6	22
50	Insulin-like Growth Factor-I (rhIGF-I) Therapy of Short Stature. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 301-15.	0.4	21
51	Physiology and Disorders of the Growth Hormone Receptor (GHR) and GH-GHR Signal Transduction. Endocrine, 2000, 12, 107-120.	2.2	20
52	Physiology of Growth. Annales Nestle, 2007, 65, 97-108.	0.1	19
53	Hyperprolactinemia with Antipsychotic Drugs in Children and Adolescents. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 1-6.	1.6	19
54	Recommended IGF-I Dosage Causes Greater Fat Accumulation and Osseous Maturation Than Lower Dosage and May Compromise Long-term Growth Effects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 839-845.	1.8	19

#	Article	IF	CITATIONS
55	Effects of heterozygosity for the E180 splice mutation causing growth hormone receptor deficiency in Ecuador on IGF-I, IGFBP-3, and stature. Growth Hormone and IGF Research, 2007, 17, 261-264.	0.5	17
56	Inaccuracy of age assessment from images of postpubescent subjects in cases of alleged child pornography. International Journal of Legal Medicine, 2013, 127, 467-471.	1.2	17
57	Specificity and Sensitivity of Insulin Staining by Aldehyde Fuchsin, Pseudoisocyanin and Toluidine Blue. Biotechnic & Histochemistry, 1970, 45, 25-27.	0.4	16
58	Reclassification of Insulin-Like Growth Factor I Production and Action Disorders. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4232-4234.	1.8	16
59	Pediatric Endo-Cosmetology and the Evolution of Growth Diagnosis and Treatment. Journal of Pediatrics, 2011, 158, 187-193.	0.9	15
60	IGF-I Treatment of Growth Hormone Insensitivity. , 1999, , 739-770.		15
61	Clinical Predictors of Mucormycosis in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 1001-4.	0.4	14
62	Sex Hormone Priming for Growth Hormone Stimulation Testing in Pre- and Early Adolescent Children Is Evidence Based. Hormone Research in Paediatrics, 2011, 75, 78-80.	0.8	14
63	A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective. Growth Hormone and IGF Research, 2016, 28, 46-50.	0.5	14
64	Off-Label Use of Recombinant IGF-I to Promote Growth: Is It Appropriate?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 505-508.	1.8	12
65	Diabetic Ketoacidosis in Childhood. Pediatric Annals, 1994, 23, 284-288.	0.3	12
66	Hyperglycemic Comas in Children: New Insights into Pathophysiology and Management. Reviews in Endocrine and Metabolic Disorders, 2005, 6, 297-306.	2.6	9
67	Arterial thrombosis resulting in amputation in a child with poorly controlled type 1 diabetes and heterozygous Factor V Leiden mutation. Pediatric Diabetes, 2006, 7, 229-231.	1.2	9
68	Insulin Injection Lipoatrophy Recidivus. Pediatric Diabetes, 2014, 15, 73-74.	1.2	9
69	Absence of hypoglycemia in response to varying doses of recombinant human insulin-like growth factor-I (rhIGF-I) in children and adolescents with low serum concentrations of IGF-I. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 199-202.	0.7	8
70	Cerebral edema in diabetic ketoacidosis and other acute devastating complications: recent observations. Pediatric Diabetes, 2005, 6, 41-49.	1.2	7
71	Classification and diagnosis of diabetes mellitus in children and adolescents. Journal of Pediatrics, 1981, 99, 320-323.	0.9	6
72	Growth Hormone Receptor Deficiency in South America: Colonial History, Molecular Biology, and Growth and Metabolic Insights. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 1107-9.	0.4	6

#	Article	IF	CITATIONS
73	IGF-I treatment of diabetes. Pediatric Diabetes, 2001, 2, 123-130.	1.2	5
74	Permanent Brain Damage from Hypernatremic Dehydration in Breastfed Infants: Patient Reports. Clinical Pediatrics, 2004, 43, 855-857.	0.4	5
75	Tanner Stage 4 Breast Development in Adults: Forensic Implications. Pediatrics, 2012, 130, e978-e981.	1.0	5
76	Accurate Determination of Height Using an Inexpensive Measuring Device. Clinical Pediatrics, 1994, 33, 172-174.	0.4	4
77	Fetal and childhood nutrition in type 2 diabetes in children and adults. Pediatric Diabetes, 2000, 1, 34-40.	1.2	4
78	Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time―by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625–38]. International Journal of Pediatric Endocrinology (Springer), 2009, 2009, 1-6.	1.6	4
79	Age estimation based on pictures and videos presumably showing child or youth pornography. International Journal of Legal Medicine, 2015, 129, 621-622.	1.2	4
80	Fetal growth, adrenocortical function and the risk for type 2 diabetes. Pediatric Diabetes, 2000, 1, 150-154.	1.2	3
81	Periarticular Hand Joint Limitation Syndromes in Diabetes. Endocrine Practice, 2014, 20, 839-842.	1.1	3
82	Branched Chain and Aromatic Amino Acids Are Associated With Insulin Resistance During Pubertal Development in Girls. Journal of Adolescent Health, 2019, 65, 313-314.	1.2	3
83	Metabolic effects of antipsychotic drugs. Pediatric Diabetes, 2006, 7, 176-186.	1.2	2
84	Autoimmune Type 2 Diabetes Mellitus and Rational Classification. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 957-9.	0.4	2
85	Academic leadership: reflections in the key of C. Journal of Pediatrics, 2004, 145, 281-282.	0.9	1
86	Growth Promotion in Turner Syndrome. Hormone Research in Paediatrics, 2012, 77, 269-270.	0.8	1
87	Sudden death of a young woman attributed to diabetic ketoacidosis. Journal of Clinical Forensic and Legal Medicine, 2013, 20, 1063-1065.	0.5	1
88	Racial variation in factors related to obesity and insulin sensitivity in children and youth. Pediatric Diabetes, 2000, 1, 82-87.	1.2	0
89	The GH-IGF-I axis and diabetes complications. Pediatric Diabetes, 2001, 2, 66-70.	1.2	0
90	Does a comprehensive rehydration regimen reduce neurologic complications associated with diabetic ketoacidosis?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 808-809.	2.9	0

#	Article	IF	CITATIONS
91	Absence of hypoglycemia in response to varying doses of recombinant human insulin-like growth factor-I (rhIGF-I) in children and adolescents with low serum concentrations of IGF-I. Acta Paediatrica, International Journal of Paediatrics, 2007, 95, 199-202.	0.7	0
92	Growth Hormone Insensitivity. , 2013, , 29-53.		0
93	Growth Hormone Insensitivity. , 2018, , 31-59.		0
94	Genetic Disorders of the Hypothalamic-Pituitary-GH/IGF-I Axis. , 2012, , 2743-2762.		0
95	Recombinant Insulin-like Growth Factor I in Growth Therapy. , 2012, , 2723-2741.		0
96	Treatment of Growth Hormone Insensitivity with IGF-I: the Ecuadorian Experience. Clinical Pediatric Endocrinology, 1994, 3, 123-126.	0.4	0